Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study

This publication has 21 references indexed in Scilit:

• Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
  The Lancet Infectious Diseases, 2024
• XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
  Cell Host & Microbe, 2024
• Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
  The Lancet Infectious Diseases, 2024
• Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
  The Lancet Infectious Diseases, 2023
• XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
  Scientific Reports, 2023
• Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
  JAMA Network Open, 2023
• Comorbidities, multimorbidity and COVID-19
  Nature Medicine, 2023
• Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
  Nature Communications, 2023
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
  New England Journal of Medicine, 2020
• Comparative analysis of two rates
  Statistics in Medicine, 1985